IGF-1 LR3
None
Technical catalog description
IGF-1 LR3 is a modified version of IGF-1 with an arginine substitution at position 3 and an added 13-amino-acid N-terminal extension that dramatically reduces IGFBP binding, extending its half-life to 20–30 hours compared to standard IGF-1’s minutes.
Unlike hGH, which must be converted to IGF-1 in the liver, LR3 is active immediately. It is used by experienced bodybuilders primarily for its systemic anabolic, recovery, and insulin-sensitizing effects during building phases. The practical appeal is twofold: it provides a direct IGF-1 signal independent of GH stimulation, and the extended half-life makes it manageable with once-daily dosing.
Unlike IGF-1 DES, which is a site-injection compound for local effects, LR3 circulates systemically and delivers body-wide anabolic signaling, improved nitrogen retention, enhanced amino acid uptake, and meaningful recovery acceleration when training volume is high.
Read next
IGF-1 LR3 is used by experienced bodybuilders who want a direct IGF-1 signal rather than relying on their GH-to-IGF-1 conversion pathway. The key difference from GH and secretagogues is mechanism: GH stimulates the liver to produce IGF-1 as an intermediary; LR3 skips that step and delivers the downstream signal directly.
The practical effects people notice are improved muscle fullness and pump (insulin-like glucose uptake into muscle), faster recovery between sessions, and better muscle hardness during a building phase. These are not subtle if the compound is real and dosed correctly. The problem is that counterfeiting is rampant in this category and many users running “IGF-1 LR3” are running nothing.
The insulin-like glucose-lowering effect is real and requires respect. It is not as dangerous as actual insulin but it is enough to cause problems in someone who doses post-workout and then skips their post-workout meal.
Low blood sugar, headaches, edema, and soft-tissue swelling
Possible numbness or nerve irritation if dose is pushed carelessly
blood glucose
IGF-1
fasting glucose
bodyweight and edema
Poor glucose control or no plan for blood sugar monitoring
Using a fragile research product without understanding storage and dosing consistency
IGF-1 LR3 is chosen by users who want to directly elevate IGF-1 activity beyond what their training and GH axis produce naturally. The appeal is: nitrogen retention, amino acid uptake, recovery speed, and muscle fullness that goes beyond what AAS alone delivers. It fits naturally into advanced building cycles where the user is already optimizing GH, training, nutrition, and anabolic compounds and wants to add the IGF-1 layer on top.
Unverified community-use description: Muscle fullness, pumps, and recovery changes are reported over time. These accounts do not establish a cycle ceiling or a validated treatment duration.
This profile does not validate workout-based dosing or cycling intervals. Product quality and glucose-lowering effects remain concerns discussed here; community instructions do not establish a regimen.
Compared with hGH, IGF-1 LR3 is more direct, more acute in onset, and more relevant if the goal is the anabolic and recovery signal rather than the broader GH-axis effects. Many advanced users run both. Compared with IGF-1 DES, LR3 is systemic while DES is a local site-injection compound. They target different parts of the same pathway. Compared with secretagogues like GHRP-2 or CJC-1295, LR3 is downstream and additive rather than competitive.